Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.7197
-0.0105 (-1.44%)
Oct 14, 2026, 4:00 PM EDT - Market closed
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Revelation Biosciences the 40,487th largest employer in the world and 6,180th in the United States.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,133,553
Market Cap
2.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9 | 0 | - | 8 | 1 |
| Dec 31, 2024 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2023 | 10 | 4 | 66.67% | 9 | 1 |
| Dec 31, 2022 | 6 | - | - | 6 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| VivoSim Labs | 15 |
| Eocene | 6 |
| Cadrenal Therapeutics | 5 |
| Mustang Bio | 4 |
| Kairos Pharma | 4 |
| XORTX Therapeutics | 3 |
REVB News
- 1 month ago - Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study - TheFly
- 1 month ago - Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Accesswire
- 2 months ago - Revelation Biosciences Quarterly report: Q2 2026 - Filings
- 2 months ago - Revelation Biosciences Earnings release: Q2 2026 - Filings
- 2 months ago - Revelation Biosciences announces results from market assessment for Gemini - TheFly
- 2 months ago - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury - Accesswire
- 2 months ago - Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire